Scale-up of Programmatic MDR TB Management (PMTM) in the Philippines ROSALIND G. VIANZON, MD, MPH NTP Manager Department of Health Philippines.

Slides:



Advertisements
Similar presentations
DOTS/ DOTS PLUS IMPLEMENTATION AND INTEGRATION Vaira Leimane State Centre of Tuberculosis and Lung Diseases of Latvia Paris, October, 28.
Advertisements

DOTS-Plus to DOTS Philippines Thelma E. Tupasi Tropical Disease Foundation Rosalind G. Vianzon NTP Manager, Philippines.
MDR-TB GLOBALLY AND IN THE REGION 2013 Dr Samiha Baghdadi Medical officer – STB WHO – EMRO Cairo March 2014.
The Re- emerging Threat of TB Magnitude of the Problem Associated Factors & challenges Current strategies Aamod Asmita Dr. Bala Dr. Arun Dr. Samraj Nisha.
Planning in line with the Stop TB Strategy and the Global Plan to Stop TB, Dr Win Maung Programme Manager National Tuberculosis Programme Ministry.
PPM-DOTS in Cambodia Working with Private Pharmacies DOTS Expansion WG Meeting Paris 15 th October 2008 Dr. Mao Tan Eang Director National Center for TB.
Improving diagnosis TB laboratory strengthening.
Engaging All Care Providers in S.E Asia Region A pproach to Health Systems Strengthening Jan Voskens. IUATLD Paris, 31 October 2006.
PPM SUBGROUP MEETING Cairo, 3-5 June 2008 Involving all health care providers in the MDR and XDR-TB response Matteo Zignol Stop TB Department World Health.
Monitoring PPM contributions – from operational research to regular reporting Knut Lönnroth Stop TB Department 5 th PPM Subgroup Meeting Cairo, 4 June.
Country Update: Tuberculosis in Thailand
Overview of strategy for FY 14 Myanmar. CAP-TB: Goal To reduce the incidence and mortality from MDR TB in Myanmar In partnership with National Tuberculosis.
Overview of current case and treatment outcome definitions Malgosia Grzemska TB Operations and Coordination Stop TB Department Consultation Impact of WHO-endorsed.
World TB Day 2011 March 24, 2011 Mavuso Centre Manzini – Kingdom of Swaziland.
Systematic TB Screening: Philippine Experience The 9th Technical Advisory Group and National TB Program Mangers meeting for TB control in the Western Pacific.
Accelerating PMDT scale up in Ethiopia
Dr R.Reesaul Chest Physician Chest Clinic P. D`or Hospital
Country Progress Report Philippines
Introduction Thailand one of 22 countries which contain 80% of the estimated tuberculosis (TB) cases in the world. Thailand ranks 17 th among the 22 high-burden.
Monitoring and Evaluation: A Review of Terms. Goals To provide better treatment for people with tuberculosis in Country X To achieve a treatment success.
Status of Revised National Tuberculosis Control Program (RNTCP) in India Dr Jitendra.
4 th National Anti-tuberculosis Drug Resistance Survey Botswana, 2007.
Xpert in the diagnostic algorithm of pulmonary TB in adult patients who are neither high risk for HIV, nor high risk for MDR-TB Preparations for the global.
MDR-TB: a fight we cannot afford to lose! Alexander Golubkov, MD, MPH Senior TB Technical Advisor.
RNTCP: DOTS Expansion and plans for DOTS-Plus
World Health Organization
DRUG-RESISTANT TB in SOUTH AFRICA: Issues & Response _ ______ _____ _ ______ _____ ___ __ __ __ __ __ _______ ___ ________ ___ _______ _________ __ _____.
Improving TB-DM Care in the Pacific: Partnerships and Progress R. Brostrom, MD-MSPH Hawaii TB Control Branch Chief Regional TB Field Medical Officer, CDC-DTBE.
Progress and Plans for PPM in the Western Pacific Region Fifth PPM DOTS Subgroup Meeting Cairo, Egypt.
“World TB day and TB in Mongolia”
Samahan ng Lusog Baga Association, Inc. (SLBAI) Ma. Cristina Brigaste, RN President Samahan ng Lusog Baga Lung Center of the Philippines.
Action Plan Good Health Situation of Population in Capital of Myanmar Yangon Division By DR MYA THIDA AYE.
Monitoring Drug Resistant Tuberculosis Treatment in Brazil through an Innovative Web-based Information System Dr. Luis Gustavo Bastos Management Sciences.
Programmatic Management of Multidrug Resistant TB (PMDT) 5 th Joint International Monitoring Mission of NTP, Thailand 23 August, 2013.
TB PUBLIC-PRIVATE MIX DOTS Dr. Team Bakkhim Deputy Director CENAT Intercontinental Hotel 7 th November, 2012 NATIONAL FORUM ON PUBLIC-PRIVATE PARTNERSHIP.
ATTAINMENT OF GLOBALLY ACCEPTABLE CURE RATE THROUGH QUALITY DOTS SERVICES IN SELECTED AREAS OF THE NATIONAL CAPITAL REGION ( ) Amelia C. Medina,
Dr. Hind E. Satti Partners In Health, Lesotho March, 2008.
Sources of Limited Access to Treatment High Cost of Treatment Lack of Pilot Projects Lack of Evidence Lack of Policy Lack of Demand.
1 Oct 2005 WHO/STB/THD World Health Organization 4 th Meeting of Subgroup on laboratory capacity strengthening Paris, France, October Ernesto Jaramillo.
DOTS-PLUS IN TANZANIA: PREPARATION PHASE Global DOTS Expansion Working Group Meeting, Paris: 28 October 2004 NTLP - MOH Prepared by: Dr. S. M. Egwaga NTLP.
Drug Resistance Pattern of Tuberculosis in India- Status Report Tuberculosis Research centre (ICMR)
Monitoring Process of the National TB Control Program (NTP) in the Philippines Anna Marie Celina G. Garfin, MD Medical Specialist IV National Center for.
TB, MDR-TB and XDR-TB in South Africa October 2006.
Public Health. TB-DOTS program Government commitment Case detection by DSSM among symptomatic patients self-reporting to health services Standard short-course.
1 Partnering to Strengthen Local Efforts Can Help Us Get to Six Million on ART Anja Giphart, MD MPH Vice President, Program Implementation Elizabeth Glaser.
Philippe Chiliade, MD, MHA Technical Advisor, Clinical Care, FHI 12 August 2008 Family Health International Implementing HIV Care & Treatment Progress.
Patient with Presumptive TB HIV Status PositiveNegative % Empiric Tx of Patients with Active TB % Empiric Tx of TB-Symptomatic Patients without True TB.
L.A. County Public Health Partnering with the Private Community to Control TB Myrna Mesrobian, MD, MPH.
1 Identifying Contribution of Community-based DOTS in Treatment Outcome of TB Patients in Four Provinces of Afghanistan Qader, Ghulam MD, DPH, MPH Senior.
Thailand TB Situation Dr. Chawetsan Namwat Director Bureau of Tuberculosis 23 August
PNG, Philippines and Vietnam. Cascade of Patient Care Action Points All enrolled patients complete their treatment Decentralize services to improve access.
Global Fund Grant Proposal Round 11: Tuberculosis Nathan Furukawa Gabriella Boyle Rebekah Miner Paa Kobina Forson Xiaoxue Huang Hunter Pugh Gap Analysis.
Programmatic Management of Drug-resistant TB (PMDT) in the Philippines
Pre-meeting Summary Shannon Barkley, MD MPH Primary Health Care Service Delivery and Safety Department (SDS) World Health Organization 11 April 2016.
PMDT IN CHINESE TAIPEI ECONOMY Anita Pei-Chun Chan, MD, PhD Medical Officer, TCDC Associated Director, TB Research Center, TCDC Assistant Professor, Institute.
Compendium of Indicators for Monitoring and Evaluating National Tuberculosis Programs.
ADDRESSING MDR-TB: The PHILIPPINE EXPERIENCE
Taipei, June Content  Introduction about Vietnam’s Programmatic Management of Drug resistant Tuberculosis (PMDT) and drug resistant tuberculosis.
Monitoring and Evaluation: A Review of Terms
2013 NTP MANUAL OF PROCEDURES Reporting
Fifth Pacific Stop TB meeting Fiji Islands, May 4-7, 2010
Richard Laing, Kelly McGoldrick
The role of the community in TB control
5th edition NTP MANUAL OF PROCEDURES Introduction and Highlights
From TB control to integrated respiratory disease control
5th DEWG meeting Conclusions
Pharmacy Sector SECTOR COMMITMENT TO END TB
5th edition NTP MANUAL OF PROCEDURES Reporting
Monitoring and Evaluation: A Review of Terms
5th edition NTP MANUAL OF PROCEDURES Chapter 1: Introduction
Presentation transcript:

Scale-up of Programmatic MDR TB Management (PMTM) in the Philippines ROSALIND G. VIANZON, MD, MPH NTP Manager Department of Health Philippines

Magnitude of MDRTB in the Philippines: Data Sources Type of Resistance New Previously Treated Phil. National Survey,1997 (Tupasi, T., et.al)1.4%14.5% National Drug Resistance Survey NTP,WHO,JICA, 2004 (Preliminary)4.4%21%

Treatment Failure Rate (Smear +), NTP Amongst NEW (%) Amongst Re-Treatment (%)

Treatment Failure* Rate (Smear +) DOTS Center at MMC Amongst NEW (%) Amongst Re-Treatment (%) * All turned out to be MDR-TB

Pilot Stage:  Initial Scope and context – GLC Pilot Project  Privately Initiated DOTS Unit at MMC as the starting point “ DOTS (+) Project at MMC ”  75% referrals from: Private practitioners  PPMD: need to harness PPs into DOTS  Laboratory capacity for culture and DST  2 nd line drugs need to be secured and assured  Sustainability - impending concern Stages of PMTM in the Philippines “ DOTS (+) ”  Goes beyond DOTS  “ DOTS (+) ”

Stage of Mainstream:  Integration of DOTS(+) into the public DOTS  Stepwise implementation  “ LCP DOTS (+) Project ”  “ LCP DOTS (+) Project ” - public counterpart  - in-house services  Referrals from both public and private MDs  Community-based approach: Decentralize to public health centers with participation from community volunteers  Absorptive Capacity – prevailing concern Stages of PMTM in the Philippines

Cohort Outcome n=281

Stage of Scale-up:  Expansion of Project into Program (PMTM) (Region: Metro Manila)  Geographic expansion (Region: Metro Manila)  Engaging more community-based facilities - PPMD units (Public and Private-initiated) - Public DOTS Hospitals (District Hospitals) - Other Public Health Centers  More decentralized approach - realistic, viable  Added complexity and financial demand Stages of PMTM in the Philippines

R5 Scale-upR2 Mainstream

DOTS Microscopy PPMD Unit at MMC (Privately-Initiated) PUBLIC Facility (1 st line drugs) NTP

Evolution of a PPMD Unit into a DOTS-Plus unit PUBLIC Facility (1 st line drugs) Microscopy Culture DST DOTS DOTS Plus

PUBLIC Facility (1 st line drugs) Microscopy Culture DST DOTS DOTS Plus Treatment Site (Health Center) Treatment Site (Health Center) LCP DOTS(+) Treatment Center Treatment Site (Health Center) Treatment Site (Health Center) KASAKA DOTS(+) Treatment Center Mainstream into the Public DOTS Culture Microscopy Culture Microscopy

8 Treatment Centers 8 Treatment Centers 4 Culture Centers MORE Treatment Sites The Scale-up 3 DST Sites CEBU

Treatment Centers: - more than 10 patients being treated at a time - more comprehensive/specialized management (e.g. LCP, KASAKA-QI) Treatment Sites: - fewer patients (<10) being treated at a time - represented by public health centers, PPMDs other public facilities, faith-based DOTS units Types of PMTM Facilities

Microscopy Culture DST Culture Types of PMTM Facilities Culture Centers: - perform culture services, NTRL supervises EQA - broader catchment areas - those identified under the DRS e.g. Cebu Ref. Lab. DST Sites: - perform DST, NTRL oversees quality of culture and microscopy - fewer but strategically located (2 Manila, 1 Cebu) - under the supervision of supranational laboratory

DOTS is STILL the OVERARCHING FRAMEWORK 1. Sustained political commitment. 2. Diagnosis of drug resistance through quality-assured culture and drug susceptibility testing (DST). 3. Uninterrupted supply of quality assured second-line anti-TB drugs. 4. Appropriate treatment strategies utilizing DOT with second-line drugs under proper management conditions. 5. Recording and reporting system designed for DOTS-Plus programs. Political commitment Quality microscopy service Regular availability of 1 st line drugs D.O.T Standardized records and reports

Steps and Requirements for the SCALE-UP Environmental scanning * Existing resources and capacities - DRS * For strategic selection of expansion sites * For strategic selection of expansion sites Advocacy to ensure political commitment Advocacy to ensure political commitment * Memorandum of Understanding (MOU) Create essential organizational structures * PMTM Task Force, PMTM Consillium, * PMTM Task Force, PMTM Consillium, Lab. SubCommittee

Policies, guidelines, standards development Human resource development * Task Analysis * Standardized training materials Network of lab services and other diagnostics Network of lab services and other diagnostics * Microscopy, EQA, Culture and DST * Chest X-ray with TBDC participation Steps and Requirements for the SCALE-UP

HRH Capacity-Building Training of Trainers Training for Monitoring and Supervision Training for Implementers Training(Region) Monitoring & Supervision(Province/City) DOTS-Plus Implementation Treatment Center DOTS-Plus Implementation Treatment Site

Scale-up of Laboratory Capacity CultureEQAMicroscopy NTRL & Other DST SitesDST Regional TB Reference Laboratory PHO/CHO Validation Center DOTS-Plus Implementation Treatment Center Supranational Laboratory

Logistics management: 2 nd line drugs, 1 st line drugs and *2 nd line drugs, 1 st line drugs and drugs for adverse reactions Steps and Requirements for the SCALE-UP SelectionNTP,TDF Distribution NTP, CHDs, LGUsProcurementTDF,GLC,WHO Utilization Tx Centers, Tx Sites Drug Cycle for 2 nd Line Drugs

Community involvement to facilitate a decentralized approach * Treatment Centers * Treatment Sites Public-Private Partnership- engaging PPMD units. Public-Private Partnership - engaging PPMD units. Private physicians need to be harnessed to the DOTS strategy to prevent them from proliferating MDRTB. Steps and Requirements for the SCALE-UP

Standardized information/data system * Records and Reports Monitoring, Supervision and Evaluation Monitoring, Supervision and Evaluation * Internal MSE * External MSE - GLC Steps and Requirements for the SCALE-UP

Access potential agencies for support (National and Local) Government (National and Local) Non-Government Agencies, Private sector External Assistance (Technical and Financial) GFATM, USAID, WHO, Others Address the 5 dimensions of sustainability: Political*Technological*Sociocultural*Economic/Financial Steps and Requirements for the SCALE-UP Institutional

Pilot Mainstream Scale-up Approach – Impact Relationship MDR Cases and Scaling-up Approach – Impact Relationship MDRs With Appropriate Management Undetected XDR Program Approach (PMTM) LCP Project MMC DOTS (+) Project

THANK YOU